Last $12.98 USD
Change Today -0.23 / -1.74%
Volume 170.7K
SRPT On Other Exchanges
As of 9:50 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

sarepta therapeutics inc (SRPT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/21/14 - $40.00
52 Week Low
12/16/14 - $12.58
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

sarepta therapeutics inc (SRPT) Details

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Its lead product candidate is Eteplirsen, an antisense PMO-based therapeutic in clinical development for the treatment of individuals with Duchenne muscular dystrophy. The company is also involved in developing treatments that are in clinical development include AVI-7288 for the treatment of Marburg virus and AVI-7100 for the treatment of influenza. In addition, it focuses on developing preclinical research product candidates for the treatment of other neuromuscular, infectious, and rare diseases. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.

146 Employees
Last Reported Date: 03/3/14
Founded in 1980

sarepta therapeutics inc (SRPT) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $580.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $457.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $377.7K
Senior Vice President, General Counsel and Co...
Total Annual Compensation: $376.9K
Senior Vice President of Technical Operations
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

sarepta therapeutics inc (SRPT) Key Developments

Glancy Binkow & Goldberg LLP Files Class Action Lawsuit Against Sarepta Therapeutics, Inc

Glancy Binkow & Goldberg LLP representing investors of Sarepta Therapeutics, Inc. has filed a class action lawsuit in the United States District Court for the District of Massachusetts on behalf of a class comprising purchasers of Sarepta securities between April 21, 2014 and October 27, 2014, inclusive. The company’s lead product candidate is eteplirsen, which is in clinical development for the treatment of Duchenne muscular dystrophy. The complaint alleges that defendants made false and/or misleading statements and/or failed to disclose to investors that: the company failed to provide sufficient data for its New Drug Application (NDA) submission for marketing approval of eteplirsen; as a result, the company’s NDA for eteplirsen would likely be filed in mid-2015, rather than the end of 2014; and, the company’s statements about Sarepta’s business, operations and prospects, including statements about eteplirsen’s prospects for FDA approval for the treatment of Duchenne muscular dystrophy, were materially false and misleading and/or lacked a reasonable basis.

Sarepta Therapeutics, Inc. - Special Call

To provide information and answer questions about DMD development program, including current and upcoming clinical trials

Sarepta Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 11:30 AM

Sarepta Therapeutics, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-10-2014 11:30 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Christopher Nishan Garabedian, Chief Executive Officer, President and Director, Sandesh Mahatme, Chief Financial Officer, Chief Accounting Officer and Senior Vice President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRPT:US $12.99 USD -0.22

SRPT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,620 GBp +54.50
Baxter International Inc $74.94 USD +0.46
Gilead Sciences Inc $96.97 USD -11.48
Hemispherx Biopharma Inc $0.24 USD +0.0006
SciClone Pharmaceuticals Inc $8.72 USD -0.13
View Industry Companies

Industry Analysis


Industry Average

Valuation SRPT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 43.9x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 24.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SAREPTA THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at